GlassScriptPhysician profile
Mary B Snell
NPI 1427042902
$737.96
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $201.56 | 2019 | |
| Merck Sharp & Dohme LLC | $79.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.92 | 2019 | |
| Pfizer INC. | $66.95 | 2019 | |
| Allergan, INC. | $52.80 | 2019 | |
| Novo Nordisk INC | $48.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.24 | 2019 | |
| Amgen INC. | $35.73 | 2019 | |
| Astellas Pharma US INC | $23.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.43 | 2019 | |
| Lilly USA, LLC | $15.43 | 2019 | |
| Genentech USA, INC. | $15.04 | 2019 | |
| Glaxosmithkline, LLC. | $13.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.48 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $13.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.